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Take Home Message 
Helmet CPAP treatment fails in up to 44% of patients with moderate-to-severe hypoxemic acute 
respiratory failure due to COVID-19 pneumonia 
TEXT 
Patients with COVID-19 pneumonia can develop hypoxemic acute respiratory failure (hARF) with the 
need for positive end-expiratory pressure (PEEP). The administration of a continuous positive airway 
pressure (CPAP) through a helmet improves oxygenation and avoids intubation [1,2]. A European 
consensus document suggests that helmet CPAP should be the first therapeutic choice for hARF 
caused by COVID-19 pneumonia, mainly for minimizing aerosol generation [3-5]. However, 
recommendations are based on experts’ opinion and consider only evidence obtained in critically ill 
COVID-19 patients [3]. The Surviving Sepsis Campaign does not recommend the administration of 
CPAP for the initial management of severe COVID-19 [6].  
In order to evaluate outcomes of COVID-19 patients with pneumonia-related hARF undergoing CPAP 
treatment, a multicenter, observational, prospective study was conducted between March 7th, 2020 
and April 21st, 2020 in three high-dependency units (HDU) at two hospitals in Milan, Italy. Adults 
(≥18 years) with hARF secondary to community-acquired COVID-19 pneumonia undergoing helmet 
CPAP treatment were consecutively recruited. Indications for helmet CPAP included all the following: 
a diagnosis of pneumonia as the only cause of hARF and a partial arterial pressure of oxygen to 
fraction of inspired oxygen (PaO2:FiO2) ratio <300 evaluated during oxygen therapy supplied for at 
least 30 minutes through either a Venturi mask (FiO2 of at least 0.50) or reservoir mask. CPAP was 
delivered through high-flow generators (VitalSigns inc., Totowa, USA; 90–140 L/min; Myo 3133A, 
Pulmodyne) using a helmet (StarMed, Italy) as interface with a PEEP valve (VitalSigns, USA). The 
presence of other causes of hARF were excluded by clinical evaluation. Patients with at least one of 
the following criteria were excluded: need for immediate intubation, Glasgow Coma Scale <15, 
respiratory acidosis, systolic blood pressure (SBP) <90 mmHg despite fluid resuscitation and/or use 
of vasopressors, swallowing disturbance with increasing risk of aspiration pneumonia, and inability 
to protect the airways. The Ethical Committees of the two hospitals approved the study (No. 
345/2020 and No. 17263/2020). Demographic, epidemiological, clinical, and laboratory data were 
recorded at admission. Arterial blood gas analysis and vital signs were recorded before CPAP, and 
within 6 hours, on day 3 and day 7 after CPAP initiation. Lung recruitability during CPAP treatment 
was defined as an increase of PaO2:FiO2 ratio of at least 30% from oxygen therapy (baseline) to CPAP 
treatment (within 6 hours). Severe pneumonia on admission was defined according to latest 
ATS/IDSA guidelines [7]. Patients were followed up to either 30-days or hospital discharge if still 
hospitalized at 30 day from HDU admission. The primary outcome was CPAP failure defined as the 
occurrence of either intubation or death due to any cause during HDU stay. According to local 
standard operating procedures, indication for intubation included the presence of either ≥1 major or 
≥2 minor criteria lasting for ≥1 hour. Major criteria were: respiratory arrest, respiratory pause with 
unconsciousness, severe hemodynamic instability (i.e., SBP <90 mmHg instead of adequate volume 
resuscitation), and intolerance to helmet CPAP leading to discontinuation of the device. Minor 
criteria were: reduction of ≥30% of basal PaO2:FiO2 ratio, PaO2:FiO2 ratio <100, 20% increase of 
PaCO2 if basal PaCO2 was ≥40 mmHg, worsening of alertness, new onset or persistent respiratory 
distress, SpO2 <90%, and exhaustion.  Achievement of the criteria did not automatically imply 
intubation of the patient, since this decision was based on a multidisciplinary discussion among the 
attending physician, the senior attending physician and the critical care physician. Secondary 
outcomes included the weaning from CPAP to oxygen therapy (CPAP success), all-cause in-hospital 
and 30-day mortality. Do-Not-Intubate (DNI) order was defined as the decision of the attending 
physician in charge (after discussion with the critical care physician) to withheld intubation and to 
use CPAP as “ceiling” treatment considering patient’s characteristics (e.g., extremely poor functional 
status prior on admission, very low predicted probability of hospital survival, patient's own opinion 
when reliable, frailty score, and comorbidities). Weaning from helmet CPAP was standardized across 
the three HDUs. Patients on helmet CPAP who did not show signs of respiratory distress (e.g. RR<25) 
and maintained a SpO2>94% with a FiO2<50% and a PEEP<=5 cmH2O underwent a weaning trial. 
Patients maintaining a PaO2:FiO2 ratio >250 on Venturi mask with a FiO2 <40% for at least 24 hours 
were considered successfully weaned from helmet CPAP. Qualitative and quantitative variables were 
summarized with frequencies (absolute and relative, percentage) and central tendency (means and 
medians) and variability (standard deviations, SD, and interquartile ranges, IQR) indicators, 
depending on their parametric distribution. A chi-squared or Fisher exact test was computed for 
qualitative variables; Student t test or Mann Whitney was used for quantitative variables with a 
parametric or non-parametric distribution, respectively. A Cox proportional hazards regression 
analysis was carried out to assess the relationship between the composite primary outcome and 
independent variables. No specific computations were carried out. All the individuals potentially 
fitting the study selection criteria were recruited when admitted at the two hospitals in Milan. A 
two-tailed p-value less than 0.05 was considered statistically significant. Statistical computations 
were performed with STATA version 16 (StatsCorp, Texas, USA). 
A total of 157 patients [74.5% males; median (IQR) age: 64 (55-75) years] with hARF [median (IQR) 
PaO2:FiO2 ratio of 142.9 (96.7-203.2)] underwent helmet CPAP with an initial median (IQR) FiO2 of 
0.6 (0.5-0.6) and mean (SD) PEEP of 10.8 (2.3) cmH2O (Table). The most prevalent comorbidities 
were arterial hypertension (44.0%), diabetes (22.9%), ischemic cardiac disease (17.2%), and chronic 
arrhythmia (10.8%). Hypoxemia generally improved when CPAP treatment was initiated: median 
(IQR) values of PaO2:FiO2 ratio at baseline on oxygen therapy [142.9 (96.7-203.2)] significantly 
improved when helmet CPAP was used after 6 hours [205.6 (140.0-271.1), p <0.0001]. However, an 
increase of at least 30% in PaO2:FiO2 ratio during helmet CPAP application in comparison to oxygen 
therapy was found only in 52% of the population. Median (IQR) duration of helmet CPAP treatment 
was 6 (3-10) days. Only 4 patients discontinued helmet CPAP because of intolerance. No patients 
were lost during follow-up. CPAP failure was observed in 70 (44.6%) patients: 34 (21.7%) were 
intubated, and 36 (22.9%) died during the HDU stay. 87 (55.4%) patients improved during the HDU 
stay, weaned to oxygen therapy and transferred to general ward. No patients were intubated during 
the first hours after CPAP initiation or under high emergency conditions (e.g. cardiac arrest). Among 
those who died in HDU, pneumonia-related deaths were detected in 26 patients, while non-
pneumonia related in 10 patients, including pulmonary embolisms (5 patients), end-stage renal 
failure (2 patients), cerebrovascular accident (1 patient), end-stage heart failure (1 patient), and 
septic shock (1 patient). Among the 34 patients who were intubated in HDU and transferred in the 
intensive care unit (ICU), 9 (26.5%) died. A total of 65 (41.4%) patients had a DNI status on HDU 
admission: 36 died and 29 survived. At the multivariable analysis (adjusted for gender, age, severe 
CAP, IL-6, and a delta of PaO2:FiO2 ratio ≥30%), CPAP failure was associated with the severity of 
pneumonia on admission [HR (95%CI): 2.9 (1.3-6.2); p-value: 0.009] and higher baseline values of IL-
6 [HR (95%CI): 1.0 (1.0-1.0); p-value <0.009]. The all-cause in-hospital and 30-day mortality rates 
were 28.7% and 28.0%, respectively.  
The rate of CPAP failure (either intubation or death) in COVID-19 patients seems to be higher in our 
study compared with the one recently reported in a multicenter, observational study which enrolled 
non-COVID-19 pneumonia patients with comparable severity of hARF (44.6% VS. 23%) [8]. Both 
intubation (21.7% VS. 11%) and mortality (22.9% VS. 12%) rates were also higher in COVID-19 
pneumonia than non-COVID-19 pneumonia patients [8]. This finding can be explained by the 
complex phenomena behind the occurrence of the respiratory failure experienced by COVID-19 
patients, which is often paralleled by local vascular micro-thrombosis, and, more importantly, by the 
absence of a treatment of proven efficacy [9].  Nevertheless, the overall mortality rate of our cohort 
was comparable to that recently reported in ICU patients [10]. A total of 55.4% of our patients with a 
median PaO2:FiO2 ratio of 136 and treated with helmet CPAP avoided intubation, and, then, were 
successfully weaned to oxygen therapy. Unfortunately, prognostic criteria which can discriminate 
responders to CPAP therapy at HDU admission are still lacking. Finally, a French study enrolled 38 
COVID patients with ARF and suggested that CPAP seems to avoid intubation especially in DNI 
patients [11]. It is difficult to compare our results with those by Oranger and coworkers for different 
reasons, including the different intervention (Boussignac and oro-nasal CPAP vs. helmet CPAP), 
unclear severity of respiratory failure (only PaO2 was reported), inclusion of patients needing O2 >6 
l/min to maintain an SpO2 >92%, which represents a selection bias (increase of the number of milder 
patients), and the absence of a mortality rate reported in the CPAP arm. 
The present study has several limitations which can limit the generalizability of our results. Among 
those, the lack of a control group and different standard operating procedures across the three 
centers, as well as the lack of important information, including the daily length of CPAP treatment, 
might reduce the inference. However, this is the first experience which evaluated outcomes in 
COVID-19 patients undergoing helmet CPAP in a multicenter, prospective study. In conclusion, the 
application of helmet CPAP in COVID-19 patients should be carefully considered and monitored to 
prevent a delayed endotracheal intubation. 
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TABLE 
Table. Baseline characteristics, CPAP treatment and outcomes of the study population according 
to CPAP failure or success. 
 
CPAP  
Success 
(n= 87) 
CPAP 
Failure 
(n= 70) 
p-value 
Demographics 
Males, n (%) 60 (69.0) 57 (81.4) 0.08 
Median (IQR) age 66 (56-75) 60 (51-72) 0.08 
     Age > 65 years, n (%) 45 (51.7) 26 (27.1) 0.07 
     Age > 75 years, n (%) 20 (23.0) 15 (21.4) 0.82 
Median (IQR) BMI 27.4 (25.1-30.2) 27.5 (23.7-29.3) 0.39 
Obesity (BMI ≥30 kg/m2), n (%) 16 (25.4) 13 (24.1) 0.87 
Current/former smoker, n (%) 17 (19.5) 10 (14.3) 0.39 
Comorbidities 
Any cardiovascular disease, n (%) 49 (56.3) 32 (45.7) 0.19 
Hypertension, n (%) 41 (47.1) 28 (40.0) 0.37 
Diabetes, n (%) 24 (27.6) 12 (17.1) 0.12 
Ischemic Cardiac Disease, n (%) 19 (21.8) 8 (11.4) 0.09 
Chronic Arrhythmias, n (%) 7 (8.1) 10 (14.3) 0.21 
Cerebrovascular disease, n (%) 9 (10.3) 4 (5.7) 0.39 
Immunosuppression, n (%) 8 (9.2) 3 (4.3) 0.35 
COPD, n (%) 7 (8.1) 3 (4.3) 0.51 
Chronic Renal Failure, n (%) 6 (6.9) 3 (4.3) 0.73 
Liver disease, n (%) 5 (5.8) 4 (5.7) 1.00 
Asthma, n (%) 1 (1.29 2 (2.9) 0.59 
Radiology 
Consolidation on chest X-ray, n (%) 66 (75.9) 58 (82.3) 0.29 
Pleural effusion, n (%) 15 (17.2) 11 (15.7) 0.80 
Pharmacological treatment 
Treatment with 
immunomodulators, n 
(%) 
None 56 (64.4) 42 (60.0) 
0.74 Anakinra 26 (29.9) 22 (31.4) 
Tocilizumab 5 (5.8) 6 (8.6) 
Hydroxychloroquine, n (%) 84 (96.6) 68 (97.1) 0.83 
Lopinavir/ritonavir, n (%) 48 (55.2) 37 (52.9) 0.77 
Remdesivir, n (%) 2 (2.3) 3 (4.3) 0.66 
Endovenous Steroids, n (%) 37 (42.5) 35 (50.0) 0.42 
Antibiotic, n (%) 84 (96.6) 66 (94.3) 0.49 
Anticoagulation  24 (27.9) 21 (30.4) 0.73 
Disease severity 
Severe pneumonia, n (%) 56 (64.4) 55 (78.6) 0.05 
Septic Shock Vasopressor, n (%) 3 (3.5) 2 (2.9) 1.00 
Aggressive Fluid resuscitation, n (%) 2 (2.3) 0 (0.0) 0.50 
Clinical variables before CPAP treatment 
Confusion, n (%) 7 (8.1) 2 (2.9) 0.30 
Mean (SD) temperature (n= 153) 37.3 (1.1) 37.6 (0.9) 0.12 
Median (IQR) systolic blood pressure 
(n= 156) 
130 (115-140) 130 (120-140) 0.87 
Median (IQR) diastolic blood pressure 
(n= 156) 
75 (70-85) 80 (70-85) 0.69 
Mean (SD) heart rate (n= 156) 88.3 (15.6) 86.5 (14.5) 0.47 
Median (IQR) respiratory rate (n= 153) 28 (24-32) 25.5 (21-30) 0.09 
     Respiratory rate ≥30 breaths per 
minute 
37 (43.5) 20 (29.4) 0.07 
Median (IQR) SpO2 (n= 154) 93 (89-97) 95.5 (90-97) 0.41 
Blood Gas Analysis before CPAP treatment 
Median (IQR) pH (n= 155) 7.48 (7.45-7.51) 7.47 (7.45-7.50) 0.91 
Mean (SD) PaCO2, mmHg (n= 157) 33.0 (5.0) 32.9 (5.9) 0.89 
Median (IQR) PaO2, mmHg (n= 157) 65 (53-83) 75.5 (60-96) 0.009 
Median (IQR) PaO2:FiO2 ratio (n= 157) 136 (95.0-204.8) 152 (100-202) 0.85 
PaO2:FiO2 
ratio 
Classes 
PaO2:FiO2 ratio ≤ 100 
mm/Hg 
23 (26.4) 18 (25.7) 
0.90 
 (100 <mm/Hg PaO2:FiO2 
ratio ≤200 mm Hg) 
39 (44.8) 34 (48.6) 
200 <mm/Hg PaO2:FiO2 
ratio ≤300 mm Hg) 
25 (28.7) 18 (25.7) 
Blood tests before CPAP treatment 
Median (IQR) white blood cells, 
cell/mm3 (n= 156) 
7,060 (5,550-9,630) 
8,000 (5,490-
10,450 
0.45 
Median (IQR) platelets, cell/mm3 (n= 
155) 
227,00 (169,000-
336,000) 
199,000 (142,000-
264,500) 
0.02 
Median (IQR) D-Dimer, µg/L (n= 126) 793 (561.0-1,242.5) 1,098 (667-2,444) 0.03 
Median (IQR) ferritin, µg/L (n= 123) 1,484 (832-2,732) 
1,558.5 (1,049-
2,830) 
0.54 
Median (IQR) IL-6, ng/L (n= 125) 46.6 (19-75) 134 (77.9-266) <0.0001 
Median (IQR) C-reactive protein, 
mg/dL (n= 157) 
13.6 (8.4-44.0) 15.6 (10.8-25.8) 0.49 
CPAP Initiation and treatment 
Median (IQR) FiO2 % (n= 154) 50 (50-60) 60 (50-70) <0.0001 
Mean (SD) PEEP cmH2O (n= 154) 10.4 (2.2) 11.4 (2.4) 0.01 
An increase of PaO2:FiO2 ratio of at 
least 20% from oxygen therapy to 
CPAP, n (%) 
53 (64.6) 33 (48.5) 0.047 
An increase of PaO2:FiO2 ratio of at 
least 30% from oxygen therapy to 
CPAP, n (%) 
51 (62.2) 27 (39.7) 0.006 
Median (IQR) days of CPAP treatment 
(n= 153) 
8 (5-14) 4 (3-7) <0.0001 
CPAP complications 
Pneumothorax n (%) 0 (0.0) 1 (1.4) 0.45 
Pneumomediastinum, n (%) 0 (0.0) 2 (2.9) 0.20 
Hemodynamic instability, n (%) 0 (0.0) 9 (12.9) 0.001 
Intolerance*, n (%) 10 (11.5) 11 (15.7) 0.44 
Ulcer, n (%) 2 (2.3) 0 (0.0) 0.50 
Study Outcomes 
Weaning from CPAP to Oxygen 
therapy, n (%) 
84 (96.6) 6 (8.6) <0.0001 
Median (IQR) days from CPAP initiation 
to weaning to Oxygen therapy (n= 87) 
7 (4-12) 7 (1-8) 0.31 
Intubation, n (%) 0 (0.0) 34 (48.6) <0.0001 
Median (IQR) days from CPAP initiation 
to intubation (n= 34) 
- 3 (2-5) - 
Mortality in HDU, n (%) 0 (0.0) 36 (51.4) <0.0001 
Median (IQR) days from CPAP initiation 
to HDU mortality (n= 36) 
- 5 (3-10) - 
Median (IQR) length of hospitalization 
(n= 138)  
18 (14-25.5) 8 (4-22) <0.0001 
In-hospital mortality, n (%) 0 (0.0) 45 (64.3) <0.0001 
Median (IQR) days from CPAP initiation 
to in-hospital mortality (n= 45) 
0 (0-0) 6 (4-11) - 
 
Footnotes: * Among them, 4 patients discontinued helmet CPAP. CPAP: continuous positive airway 
pressure; IQR: 25th-75th interquartile range; BMI: body mass index; COPD: chronic obstructive 
pulmonary disease; SD: standard deviation; PEEP: positive end-expiratory pressure; PaO2: partial 
arterial pressure of oxygen; FiO2: fraction of inspired oxygen; HDU: high dependency unit 
 
